Tacalyx is a spin-off from Max-Planck-Institute of Colloids and Interfaces (MPICI). Several years of research at MPICI have focused on TACA synthesis and characterization as well as nanobody generation. TACALYX investigates TACA biology based on this platform. The ability to synthesize pure isolates using solid phase synthesis represents an important step forward and facilitates the identification of specific antibodies and their subsequent characterization. Prof. Dr. Peter Seeberger, Director at the MPICI, has developed the chemical basis for automated glycan assembly, a feat previously deemed impossible allowing the general synthesis of this largest class of biopolymers. This access to glycans previously inaccessible in larger amounts is central to Tacalyx’s activities.